Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Manifesting carriers of X-linked myotubular myopathy

2020; Wolters Kluwer; Volume: 6; Issue: 5 Linguagem: Inglês

10.1212/nxg.0000000000000513

2376-7839

Lucas Santos Souza, Camila de Almeida, Guilherme Lopes Yamamoto, Rita de Cássia M. Pavanello, Juliana Gurgel‐Giannetti, Silvia Souza da Costa, Isabela Pessa Anequini, Silvana Amanda do Carmo, Jaqueline Yu Ting Wang, Marília O. Scliar, Erick C. Castelli, Paulo Alberto Otto, Edmar Zanoteli, Mariz Vainzof,

Muscle Physiology and Disorders

To analyze the modulation of the phenotype in manifesting carriers of recessive X-linked myotubular myopathy (XLMTM), searching for possible genetic modifiers.Twelve Brazilian families with XLMTM were molecularly and clinically evaluated. In 2 families, 4 of 6 and 2 of 5 manifesting female carriers were identified. These females were studied for X chromosome inactivation. In addition, whole-exome sequencing was performed, looking for possible modifier variants. We also determined the penetrance rate among carriers of the mutations responsible for the condition.Mutations in the MTM1 gene were identified in all index patients from the 12 families, being 4 of them novel. In the heterozygotes, X chromosome inactivation was random in 3 of 4 informative manifesting carriers. The disease penetrance rate was estimated to be 30%, compatible with incomplete penetrance. Exome comparative analyses identified variants within a segment of 4.2 Mb on chromosome 19, containing the killer cell immunoglobulin-like receptor cluster of genes that were present in all nonmanifesting carriers and absent in all manifesting carriers. We hypothesized that these killer cell immunoglobulin-like receptor variants may modulate the phenotype, acting as a protective factor in the nonmanifesting carriers.Affected XLMTM female carriers have been described with a surprisingly high frequency for a recessive X-linked disease, raising the question about the pattern of inheritance or the role of modifier factors acting on the disease phenotype. We demonstrated the possible existence of genetic mechanisms and variants accountable for the clinical manifestation in these women, which can become future targets for therapies.